================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2002
THE COOPER COMPANIES, INC.
(Exact name of registrant as specified in its charter)
Delaware 1-8597 94-2657368
(State or other jurisdiction (Commission File Number) (IRS Employer Identification No.)
of incorporation)
6140 Stoneridge Mall Road, Suite 590, Pleasanton, California 94588
(Address of principal executive offices)
(925) 460-3600
(Registrant's telephone number, including area code)
================================================================================
ITEM 5. Other Events.
On June 4, 2002, The Cooper Companies, Inc. issued a press release reporting
results for its second quarter fiscal 2002. A copy of this release is attached
and incorporated by reference.
Internet addresses in the release are for information purposes only and are not
intended to be hyperlinks to other Cooper Companies information.
ITEM 7. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit
No. Description
- ------- -----------
99.1 Press Release dated June 4, 2002 of The Cooper Companies, Inc.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
THE COOPER COMPANIES, INC.
By /s/ Stephen C. Whiteford
----------------------------------------
Stephen C. Whiteford
Vice President and
Corporate Controller
(Principal Accounting Officer)
Dated: June 11, 2002
EXHIBIT INDEX
Exhibit Sequentially
No. Description Numbered Page
- ------- ----------- -------------
99.1 Press Release dated June 4, 2002 of The Cooper
Companies, Inc.
STATEMENT OF DIFFERENCES
The British pound sterling sign shall be expressed as....................'L'
[THE COOPER COMPANIES LETTERHEAD]
NEWS RELEASE
CONTACT:
Norris Battin
The Cooper Companies, Inc.
ir@coopercompanies.com
----------------------
FOR IMMEDIATE RELEASE
THE COOPER COMPANIES REPORTS SECOND QUARTER RESULTS
Revenue Up 26% to $72 Million; EPS 64 Cents
2002 Guidance Raised
LAKE FOREST, Calif., June 4, 2002-- The Cooper Companies, Inc. (NYSE: COO) today
reported results for its second fiscal quarter ended April 30, 2002.
o Revenue $72 million, 26% above second quarter 2001; CooperVision up
27%, CooperSurgical up 20%.
o Earnings per share up 10% to 64 cents; trailing twelve months $2.68.
o Cash flow per share (pretax income from continuing operations plus
depreciation and amortization) $1.05; trailing twelve-months $4.36.
o Days of Sales Outstanding in receivables 73 days, down 15% from 86
days at the end of the first quarter, excluding the impact of recent
acquisitions.
Forward Guidance
For the third fiscal quarter of 2002, Cooper estimates revenue between $84
million and $87 million, 37% to 42% above the third quarter of 2001, with
earnings per share ranging from $.81 to $.84. Third quarter 2002 CooperVision
revenue is expected to range between $66 million and $68 million and
CooperSurgical revenue about $19 million.
For fiscal 2002, Cooper estimates revenue between $310 million and $315 million,
a 32% to 35% increase, and has raised earnings per share guidance to $3.07 to
$3.12 from the previous estimate of $3.05 to $3.10.
For fiscal 2003, Cooper estimates revenue between $380 million and $400 million
with earnings per share ranging from $3.95 to $4.05.
Business Unit P&L Highlights ($'s in millions)
- -----------------------------------------------------------------------------------------------------------
Three Months Ended April 30,
- -----------------------------------------------------------------------------------------------------------
Revenue Operating Income
- -----------------------------------------------------------------------------------------------------------
% % %Revenue %Revenue
2002 2001 Inc. 2002 2001 Inc. 2002 2001
---- ---- ---- ---- ---- ---- ---- ----
- -----------------------------------------------------------------------------------------------------------
CVI $56.1 $44.0 27% $12.3 $12.9 (5)% 22% 29%
CSI 15.8 13.2 20% 4.1 2.3 78 26% 17%
------ ------ ------ ------
Subtotal 71.9 57.2 26% 16.4 15.2 8% 23% 27%
HQ Expense - - - (1.7) - - -
------
(1.6)
------
- -----------------------------------------------------------------------------------------------------------
TOTAL $71.9 $57.2 26% $14.7 $13.6 8% 20% 24%
====== ====== ====== ======
Six Months Ended April 30,
- -----------------------------------------------------------------------------------------------------------
Revenue Operating Income
- -----------------------------------------------------------------------------------------------------------
% % %Revenue %Revenue
2002 2001 Inc. 2002 2001 Inc. 2002 2001
---- ---- ---- ---- ---- ---- ---- ----
- -----------------------------------------------------------------------------------------------------------
CVI $98.2 $80.4 22% $23.6 $22.4 6% 24% 28%
CSI 31.8 26.8 19% 7.6 4.1 84% 24% 15%
------ ------ ------ ------
Subtotal 130.0 107.2 21% 31.2 26.5 18% 24% 25%
HQ Expense - - - (3.4) - - -
------
(3.2)
------
- -----------------------------------------------------------------------------------------------------------
TOTAL $130.0 $107.2 21% $27.8 $23.3 19% 21% 22%
====== ====== ====== ======
- -----------------------------------------------------------------------------------------------------------
Note: Following our implementation of Statement of Financial Accounting
Standards No. 142, "Goodwill and Other Intangible Assets" at the beginning of
this year, we no longer amortize goodwill. Goodwill amortization included in
2001 results reduced operating income by $911,000 in the three-month period and
$1.8 million in the six-month period.
Second Quarter Operating Highlights
CooperVision
CVI's worldwide soft lens revenue, including two months of revenue from
Biocompatibles Eyecare, Inc. which Cooper acquired on February 28, 2002, grew
33% during the second quarter, and 26% through the first half.
Excluding revenue from Biocompatibles, total soft lens revenue grew 4% during
the fiscal second quarter and 10% for the first half of the year. CVI faced a
difficult second quarter comparison, as during the second quarter of 2001, Rohto
Pharmaceuticals, its partner in Japan, purchased $2.2 million of initial stock
of quarterly planned replacement lenses. This order was not repeated in the
second quarter of 2002. Excluding the Rohto order, second quarter soft lens 2002
revenue ex-Biocompatibles increased 10% in constant currency in the quarter and
15% year to date.
Worldwide sales of all specialty soft contact lenses including toric, cosmetic,
aspheric and multifocal products grew 23% during the quarter and 24% for the
first half of the year. Sales of toric contact lenses, which correct
astigmatism, increased 10% both during the quarter and year to date, about the
same rate of growth as the total toric segment. CVI estimates that it currently
holds about 33% of the worldwide segment for toric contact lenses, accounting
for 41% of CVI's year-to-date soft lens revenue.
Quarterly CVI Product Revenue Highlights
o All disposable and planned replacement products, which account for
over 75% of CooperVision's worldwide business, grew 30% in the second
quarter and 26% for the six-month period.
o CVI's brands of disposable toric lenses, those replaced after two
weeks, continue to gain market share and are now selling more than $1
million per month. Revenue for these products more than doubled over
the comparable quarter a year ago. Disposable toric lenses are the
fastest growing products in the worldwide toric segment of the contact
lens market and account for about 35% of the total.
o Together, CVI's disposable and planned replacement toric lenses, those
used monthly and quarterly, grew 6% in the quarter and 10% for the
first half. These products account for over 80% of the worldwide toric
segment.
Quarterly CVI Geographic Revenue Highlights
o Soft contact lens revenue in the United States, about 55% of CVI's
business, grew 15% in a U.S. market that grew about 7% in the first
calendar quarter, according to recent market data.
o Soft lens sales in markets outside of the United States, more than 40%
of CVI's total revenue in the quarter, grew 64%.
o European soft lens revenue, about 35% of CVI's total revenue, more
than doubled, as total toric lens business grew 90% over last year's
second quarter.
Integration of Biocompatibles
In February, CooperVision announced the acquisition of Biocompatibles Eye Care,
Inc., the contact lens business of Biocompatibles plc (LSE: BII), for 'L'68
million (about $97 million).
Biocompatibles Eye Care (Biocompatibles), the world's sixth largest contact lens
manufacturer, had worldwide revenue in calendar 2001 of about $70 million, with
about $50 million outside of North America. The Proclear line of products,
manufactured with proprietary technology that helps enhance tissue-device
compatibility, accounted for about 45% of revenue. Proclear lenses are often
indicated for patients experiencing mild discomfort relating to dryness during
lens wear, a condition that often causes patients to drop out of lens wear.
At the time of the acquisition, Cooper said that it expected transition expenses
in the second quarter of fiscal 2002 to reduce EPS by approximately 11 cents and
that the transaction would be cumulatively neutral to EPS for the eight-month
period ending October 31, 2002 and accretive thereafter. The integration of the
businesses is proceeding as planned, and Biocompatibles is expected to be
neutral or accretive to earnings per share in the third quarter of 2002 and
accretive in the fourth quarter.
CVI estimates that Biocompatibles will add more than $45 million to CVI's
worldwide revenue in the eight months of 2002 following the acquisition and
between $75 million and $80 million in 2003, following selected product and
market rationalization.
In 2003, Biocompatibles is expected to contribute about 50 cents to Cooper's
earnings per share and 79 cents in 2004.
New products
Sales of CVI's Frequency Multifocal are ahead of expectations. This product has
been placed in 900 practitioner offices to date in the United States, and CVI
expects 3,000 office placements by year end. CVI will begin a rollout of
Frequency Multifocal in Europe by the end of the third quarter.
Updated sales estimates indicate that CVI's line of cosmetic lenses should reach
about $17 million in revenue in fiscal 2002, about $3 million below previous
expectations. Revenue from Frequency Multifocal and the newly acquired Proclear
line should offset this shortfall.
CooperSurgical
Second quarter revenue at CooperSurgical (CSI), the Company's women's healthcare
medical device business, increased 20% to $15.8 million and is up 19% year to
date. Organic growth from existing gynecology products in the second quarter of
2002 was 10%. CSI expects revenue of about $40 million in the second six months
of fiscal 2002.
CSI's operating margin improved 9% above the prior year's quarter to 26%.
CSI New Business Activities
o At the meeting of the American College of Obstetricians and
Gynecologists in April, CSI introduced the Guardian Vaginal Retractor,
a device used to facilitate episiotomies and the repair of vaginal
lacerations. CSI expects revenue for this product of about $5 million
in the next two to three years.
o Also in April, CSI completed the acquisition of the bone densitometry
business of Norland Medical Systems, Inc. Norland's densitometry
products, which had 2001 revenue of $8.5 million, are used in the
evaluation of osteoporosis.
o Building on its strategy to develop a franchise in the infertility
market, in May CSI acquired Ackrad Laboratories, Inc., a developer and
manufacturer of medical devices used primarily in the assessment of
infertility and other gynecological disorders. Ackrad had revenue of
$5.3 million in 2001.
Tax Rate
As a result of the greater percentage of business outside the United States due
to the Biocompatibles acquisition and the rapid growth of CVI's international
subsidiaries, Cooper's effective tax rate (ETR) (income tax expense divided by
pretax income) was 25% for the quarter. If the tax rate had been 27% for the
quarter, the ETR currently projected for the full fiscal year, earnings per
share would have been 62 cents.
Balance Sheet Items
Cooper recently improved its receivable collections following difficulties
caused by the installation of a new enterprise reporting system at CVI. These
problems resulted in an unusually high level of Days of Sales
Outstanding (DSO's) at the end of 2001 and the first quarter of 2002. At the end
of the current quarter, Cooper's DSO's (excluding the newly acquired operations
of Biocompatibles and Norland Medical) were 73 days, down 15% from 86 days at
the end of the first quarter. DSO's are expected to return to their target level
of 70 to 72 days by the end of the fiscal year.
Inventories have reached a level where desired service levels can be maintained.
During 2000, inventory levels fell below acceptable levels and CVI had
difficulty efficiently supporting the more than 500 thousand stock keeping items
it carries in its inventory. This wide breadth of inventory is necessary to
service CVI's extensive range of toric lens parameters that allows practitioners
the widest choice of fitting alternatives in the industry.
New Credit Facility
In May, Cooper announced the successful syndication of a new $225 million bank
credit facility. The facility is comprised of a $75 million five-year term loan
with an interest only payment in the first year then fully amortized in the next
four years, and a $150 million three year revolving credit facility.
Interest rates under the new facility are based on LIBOR plus additional basis
points predicated on Cooper's ratio of debt to its earnings before interest,
taxes, depreciation and amortization (EBITDA.) These range from 125 to 225 basis
points for the term loan and from 100 to 200 basis points for the revolver. At
the Company's option, it can choose to pay a base rate that is within a range
above the prime rate.
Cooper plans to use the facility for general corporate purposes, including
acquisitions, and capital expenditures. At the closing, Cooper paid off $62
million under its existing line of credit and 'L'44 million in notes owed to
Biocompatibles International plc as a result of Cooper's purchase of
Biocompatibles Eyecare, Inc.
A total of $44 million of the credit line had been temporarily restricted
pending completion of certain British statutory procedures. These have been
completed and the restriction has been removed.
Earnings per Share
All per share amounts mentioned in this report refer to diluted per share
amounts from continuing operations.
Conference Call
The Cooper Companies will hold a conference call to discuss its second quarter
results today at 2 p.m. Pacific Daylight Time. To access the live call, dial
1-800-500-0177. A replay will be available at 1-888-203-1112 approximately one
hour after the call ends and remain available for five days. The access code for
both calls is 278298. This call will also be broadcast live on The Cooper
Companies' website, www.coopercos.com and at www.bestcalls.com and
www.streetevents.com.
Forward-Looking Statements
Some of the information included in this news release contains "forward-looking
statements" as defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include all statements regarding anticipated growth
in our revenue, anticipated market conditions and results of operations. To
identify forward-looking statements look for words like "believes," "expects,"
"may," "will," "should," "seeks," "intends," "plans," "estimates" or
"anticipates" and similar words or phrases. Discussions of strategy, plans or
intentions often contain forward-looking statements. These, and all
forward-looking statements, necessarily depend on assumptions, data or methods
that may be incorrect or imprecise.
Events, among others, that could cause actual results and future actions to
differ materially from those described in forward-looking statements include
major changes in business conditions, a major disruption in the operations of
our manufacturing facilities, new competitors or technologies, the impact of an
undetected virus on our computer systems, acquisition integration delays or
costs, increases in interest rates, foreign currency exchange exposure,
investments in research and development and other start-up projects, dilution to
earnings per share from acquisitions or issuing stock, regulatory issues,
changes in tax laws, significant environmental cleanup costs above those already
accrued, litigation costs including any related settlements, cost of business
divestitures, the requirement to provide for a significant liability or to write
off a significant asset, changes in accounting principles or estimates, and
other factors described in our Securities and Exchange Commission filings,
including the "Business" section in our Annual Report on Form 10-K for the year
ended October 31, 2001. We caution investors that forward-looking statements
reflect our analysis only on their stated date. We disclaim any intent to update
them except as required by law.
Corporate Information
The Cooper Companies, Inc. and its subsidiaries develop, manufacture and market
specialty healthcare products. Corporate offices are located in Lake Forest and
Pleasanton, Calif. A toll free interactive telephone system at 1-800-334-1986
provides stock quotes, recent press releases and financial data. Cooper's World
Wide Web address is www.coopercos.com.
CooperVision, Inc., markets a broad range of contact lenses for the vision care
market. Headquartered in Lake Forest, Calif., it manufactures in Huntington
Beach, Calif., Rochester, N.Y., Norfolk, Va., Adelaide, Australia, Farnborough
and Hamble, England, Madrid, Spain and Toronto. Its Web address is
www.coopervision.com.
CooperSurgical, Inc., with operations in Trumbull, Conn., Fort Atkinson, Wis.,
Malmo, Sweden, Montreal and Berlin, markets diagnostic products, surgical
instruments and accessories for the gynecological market. Its Web address is
www.coopersurgical.com.
Trademarks of The Cooper Companies, Inc., its subsidiaries and affiliates are
italicized.
(FINANCIAL STATEMENTS FOLLOW)
# # #
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Condensed Statements of Income
(In thousands, except for per share amounts)
(Unaudited)
Three Months Ended Six Months Ended
April 30, April 30,
--------------------- ---------------------
2002 2001 2002 2001
---------- --------- --------- ---------
Net sales $ 71,910 $ 57,182 $130,022 $107,158
Cost of sales 27,746 19,713 48,373 36,503
-------- -------- -------- --------
Gross profit 44,164 37,469 81,649 70,655
Selling, general and administrative expense 28,171 21,755 51,384 43,170
Research and development expense 918 897 1,775 1,781
Amortization of intangibles 392 1,187 700 2,409
-------- -------- -------- --------
Operating income 14,683 13,630 27,790 23,295
Interest expense 1,441 901 2,334 1,900
Other income (loss), net (18) (49) 1,018 777
-------- -------- -------- --------
Income before income taxes 13,224 12,680 26,474 22,172
Provision for income taxes 3,306 3,970 7,151 7,153
-------- -------- -------- --------
Net income $ 9,918 $ 8,710 $ 19,323 $ 15,019
======== ======== ======== ========
Diluted earnings per share $ 0.64 $ 0.58 $ 1.24 $ 1.00
======== ======== ======== ========
Number of shares used to compute earnings
per share 15,564 15,124 15,548 14,976
======== ======== ======== ========
Memo:
Cash flow (income before income taxes plus
depreciation and amortization) per
diluted share. Includes amounts for
depreciation of $2,660 and $1,344 in the
three months ended and $4,445 and $2,658
in the six months ended
April 30, 2002 and 2001, respectively $ 1.05 $ 1.01 $ 2.04 $ 1.82
======== ======== ======== ========
Note: Following our implementation of Statement of Financial Accounting
Standards No. 142, "Goodwill and Other Intangible Assets" at the beginning of
this year, we no longer amortize goodwill. Goodwill amortization included in
2001 results reduced operating income by $911,000 and $1.8 million in the three-
and six-month periods, respectively
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Condensed Balance Sheets
(In thousands)
(Unaudited)
April 30, October 31,
2002 2001
-------------- -------------
ASSETS
Current assets:
Cash and cash equivalents $ 17,033 $ 12,928
Trade receivables, net 66,563 55,318
Marketable securities 4,016 7,982
Inventories 73,181 51,153
Deferred tax assets 20,604 17,308
Other current assets 17,197 10,516
-------- --------
Total current assets 198,594 155,205
-------- --------
Property, plant and equipment, net 88,492 61,028
Goodwill 199,997 131,732
Other intangibles, net 17,319 13,890
Deferred tax asset 24,286 31,246
Other assets 3,243 3,748
-------- --------
$531,931 $396,849
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Short-term debt $ 93,770 $ 8,249
Other current liabilities 86,948 59,724
-------- --------
Total current liabilities 180,718 67,973
-------- --------
Long-term debt 70,790 60,553
Other liabilities 3,831 12,039
-------- --------
Total liabilities 255,339 140,565
-------- --------
Stockholders' equity 276,592 256,284
-------- --------
$531,931 $396,849
======== ========